SLC5A2 and hydrops fetalis: However, breakthrough randomized controlled trial data on the use of sodium—glucose co-transporter 2 (SGLT2) inhibitors in patients with HFpEF demonstrated reduced composite of cardiovascular death or HF hospitalizations.8,9 Following these trials, updated clinical practice guidelines on HFpEF have been published in recent years.